Further study will help clarify the link between partial ATRX loss in gliomas with the presence of ALT in order to more effectively use ATRX as a surrogate marker for the ALT pathway for diagnostic [56], prognostic [34, 57], and, potentially, therapeutic purposes [29, 58]. This evidence concerns the gene GPT and glioma.